by Peter Ciszewski | May 2, 2018
Jan-Anders Karlsson discusses Verona Pharma’s lead candidate, RPL554, as a potential therapy for cystic fibrosis (CF) patients and his company’s work with theCystic Fibrosis Trust. The Cystic Fibrosis Trust is the only UK-wide charity dedicated to...
by Peter Ciszewski | May 1, 2018
Positive results from the Fostamatinib in Thrombocytopenia (FIT) Phase 3 clinical program of fostamatinib disodium hexahydrate (Tavalisse) were published in the American Journal of Hematology this week for the treatment of adults with chronic immune thrombocytopenia...
by Peter Ciszewski | May 1, 2018
Chris Garabedian looks back to his time at Sarepta and his legacy...
by Peter Ciszewski | Apr 30, 2018
Stefan Weber, CEO of Newron Pharmaceuticals discusses his company’s clinical trial strategy for developing drugs for Rett Syndrome. Newron is focused on the development of novel therapies for patients with diseases of the central and peripheral nervous...
by Peter Ciszewski | Apr 28, 2018
Rob Neville of Savara Pharmaceuticals discusses some of the challenges of diangosing PAP and NTM lung infection, two diseases Savara targets. Molgradex is an inhaled formulation of recombinant human GM-CSF that is being developed for the treatment of autoimmune...
